Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
Single Afternoon Dose of ICS Linked to Better Lung Function and Reduced Inflammation in Asthma
The chronotherapeutic approach aligns treatment with peak glucocorticoid sensitivity, so may mitigate onset of the inflammatory cascade that triggers nocturnal exacerbations.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
AstraZeneca's Triple Inhaled Therapy Meets Primary Endpoints in Phase 3 Trials of Uncontrolled Asthma
The KALOS and LOGOS registration trials in patients with uncontrolled asthma compared the triple fixed dose BGF with dual combination therapy.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Mepolizumab Reduces AER in COPD Leading to Emergency Care by 35%: MATINEE Findings Published in NEJM
Mepolizumab also cut annualized exacerbation rates by 21% across the full study cohort and by 31% in a subgroup of participants with chronic bronchitis only.
Perceived Stress Tied to Worsened Respiratory Outcomes, Decreased QoL in Adults with COPD
Researchers reported higher levels of perceived stress were associated with worse respiratory outcomes, particularly among individuals with severe COPD.